Drug Profile
Research programme: biosimilar therapeutics - Turgut Ilacari
Latest Information Update: 07 Jun 2023
Price :
$50
*
At a glance
- Originator Turgut Ilac
- Class Antibodies; Recombinant proteins
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer; Haemolytic uraemic syndrome; Immunological disorders; Paroxysmal nocturnal haemoglobinuria
Most Recent Events
- 31 May 2023 Selexis has merged with KBI Biopharma to form KBI Biopharma
- 28 Jan 2022 No recent reports of development identified for research development in Haemolytic-uraemic-syndrome in Turkey
- 28 Jan 2022 No recent reports of development identified for research development in Paroxysmal-nocturnal-haemoglobinuria in Turkey